<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669331</url>
  </required_header>
  <id_info>
    <org_study_id>DPM-B-305</org_study_id>
    <nct_id>NCT00669331</nct_id>
  </id_info>
  <brief_title>Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis</brief_title>
  <official_title>: A Phase III Multicenter, Randomized, Parallel Group, Controlled, Double Blind Study to Investigate the Safety and Efficacy of Inhaled Mannitol Over 12 Months in the Treatment of Bronchiectasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmaxis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      No gold standard therapy exists for clearing mucus from the airways of patients with
      bronchiectasis. While rhDNase has a proven place in the treatment of cystic fibrosis (CF), it
      failed to improve Forced expiratory volume in one second (FEV1) in a short-term non-CF
      bronchiectasis study and has been shown to be detrimental after 6 months therapy in non CF
      bronchiectasis, moreover it has no proven effect on mucociliary clearance. Hypertonic saline
      has been shown to have a comparable mode of action to inhaled mannitol, but has yet to be
      examined as a long term treatment option in bronchiectasis.

      The purpose of this study is to examine the efficacy and safety of 52 weeks treatment with
      inhaled mannitol in subjects with non-cystic fibrosis bronchiectasis. Previous studies with
      inhaled mannitol have demonstrated improvement in mucociliary clearance; mucus rehydration;
      improvement in quality of life and respiratory symptoms in patients with bronchiectasis and
      pulmonary function in cystic fibrosis. The results of this current study in combination with
      a recently completed 3 month study seek to confirm these early findings and to extend the
      evidence to support its use as a mucoactive therapy in subjects with bronchiectasis.

      We hypothesize that mannitol will improve the overall health and hygiene of the lung through
      regular and effective clearing of the mucus load. As a consequence of the reduction in mucus
      load and inflammatory process, the frequency of bronchiectasis related pulmonary
      exacerbations and the need for exacerbation related antibiotic treatment should fall. Days in
      hospital and community health care costs are expected to change in line with improvements in
      respiratory health.

      Finally, we plan to demonstrate that inhaled mannitol is safe and well tolerated over a 52
      week period. We will test these hypotheses using 400 mg mannitol twice daily (BD) against
      control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Graded Pulmonary Exacerbations</measure>
    <time_frame>52 weeks</time_frame>
    <description>A graded pulmonary exacerbation was defined as a worsening in signs and symptoms requiring a change in treatment (Center for Drug Evaluation and Research (CDER), 2007). Grade I was required 3 main signs and symptoms, Grade II 2 main signs and symptoms and Grade III 1 main and one or more minor signs and symptoms. Main signs and symptoms were increased cough, sputum volume or sputum purulence. Minor were upper respiratory tract infection, fever, increased wheezing, increased dyspnea, increase in respiratory rate, increase in cardiac frequency of &gt;20%, and increased malaise, fatigue or lethargy. Rate is defined as the number of all GPE events observed in one treatment year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the St. Georges Respiratory Questionnaire (SGRQ) Total Score</measure>
    <time_frame>52 weeks</time_frame>
    <description>The SGRQ was collected at baseline, week 6, week 16, week 28, week 40 and week 52. Change in total score was calculated from baseline. Total scores are a weighted sum across all questions. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. Higher scores indicate lower quality of life. Outcome data table gives the raw mean total score at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic Use Prescribed for Treated Pulmonary Exacerbations</measure>
    <time_frame>52 weeks</time_frame>
    <description>Rate of antibiotic treated graded pulmonary exacerbations, using the same definition of a graded pulmonary exacerbation as the primary endpoint. A graded pulmonary exacerbation was considered to be anti-biotic treated if use of oral, IV or inhaled antibiotic use was recorded related to the GPE event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Graded Exacerbation</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time to first graded exacerbation is defined as the duration (in months) from the randomisation date to the start of the first reported graded PE during the on-treatment period. Patients without reported graded PE event will be censored at the last participation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Graded Exacerbations</measure>
    <time_frame>52 weeks</time_frame>
    <description>Duration of graded exacerbations is defined as the number of days with graded PE within one treatment year. Mean days estimated via negative binomial model with treatment, region and baseline pulmonary exacerbation rate as predictors, with log of follow-up time as the offset variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Volume</measure>
    <time_frame>52 weeks</time_frame>
    <description>24 hour sputum weight, measured at baseline, week 6, week 16, week 28, week 40, week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime Sleepiness Scores</measure>
    <time_frame>52 weeks</time_frame>
    <description>Epworth Sleepiness Scale (ESS) score was calculated as the sum of scores for each of eight individual questions, such that a total score of zero represents no daytime sleepiness, and a total score of 24 represents the maximum degree of daytime sleepiness. Measured at baseline, 6 weeks, 16 weeks, 28 weeks, 40 weeks, 52 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Change in FEV1 (Forced Expiratory Volume in One Second)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Change in FVC (Forced Vital Capacity)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Change in FEV1/FVC</measure>
    <time_frame>52 weeks</time_frame>
    <description>FEV1 expressed as a ratio of FVC. Endpoint is expressed as a percentage ie FEV1/FVC*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function - Change in FEF25-75 (Forced Expiratory Flow Rate Averaged Over 25th -75th Percentile of FVC)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile - Sputum Microbiology</measure>
    <time_frame>52 weeks</time_frame>
    <description>sputum microbiology assessed as the presence of abnormal flora in sputum sample taken at any post baseline visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile - Clinical Chemistry</measure>
    <time_frame>52 weeks</time_frame>
    <description>Clinical chemistry was assessed as clinically significant abnormal liver function test and clinically significant abnormal urea/electrolyte test at any point post baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile - Hematology</measure>
    <time_frame>52 weeks</time_frame>
    <description>hematology assessed as clinically significant abnormal FBC (Full Blood count) at any point post baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>â€¢ (Exploratory) Number of Hospitalizations Due to Pulmonary Exacerbations</measure>
    <time_frame>52 weeks</time_frame>
    <description>Mean rate of hospitalisations (number/year) summarised and analysed to take account of differing follow-up times.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health Related Costs of Treating Patients With Bronchiectasis</measure>
    <time_frame>52 weeks</time_frame>
    <description>In the presence of a significant primary endpoint, these data were intended to be derived using the trial data together with external information (Note as the primary objective of this study did not reach statistical significance, health related costs were not assessed)</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Status and Utility Scores</measure>
    <time_frame>52 weeks</time_frame>
    <description>In the presence of a significant primary endpoint, these data were intended to be derived from the trial data and external information (Note as the primary objective of this study did not reach statistical significance, differences in health status and utility scores were not assessed)</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Related Quality of Life (HRQL) and Quality Adjusted Life Years (QALYs) by Treatment Group Using Utility Scores From the Health Utilities Index Questionnaire</measure>
    <time_frame>52 weeks</time_frame>
    <description>In the presence of a significant primary endpoint, these data were intended to be derived using the trial data and external information (Note as the primary objective of this study did not reach statistical significance, HRQL and QALYs were not collected).</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost Effectiveness of Treating Patients With Bronchiectasis With Inhaled Mannitol</measure>
    <time_frame>52 weeks</time_frame>
    <description>In the presence of a significant primary endpoint, these data were intended to be derived using the trial data and external information (Note as the primary objective of this study did not reach statistical significance, cost effectiveness was not collected).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">485</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>Mannitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled mannitol 400mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched control - inhaled mannitol 50mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled mannitol</intervention_name>
    <description>400mg dose of Mannitol BD (twice a day) for 52 weeks</description>
    <arm_group_label>Mannitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched control</intervention_name>
    <description>50mg dose of Mannitol BD (twice a day) for 52 weeks</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Have given written informed consent to participate in this study in accordance with
             local regulations

          2. Have documented evidence of confirmed diagnosis of (non-cystic fibrosis)
             bronchiectasis by computed tomography (CT), High resolution computed tomography (HRCT)
             or bronchogram

          3. Be aged 18 - 85 years inclusive, male and female

          4. Have FEV1 (Forced expiratory volume in one second) â‰¥ 40% and â‰¤85% predicted* and â‰¥1.0L
             (*according to NHANES III predicted tables) measured at Visit 0A (V0A)

          5. Clinician documented history of at least 2 pulmonary exacerbations, each requiring
             antibiotic therapy, in the last 12 months prior to Visit 0A (V0A) and a total of at
             least 4 in the last 2 years prior to Visit 0A

          6. Have a total SGRQ (St George's respiratory questionnaire) score of â‰¥30 at Visit 0B
             (V0B)

          7. Have a production of â‰¥10g of sputum at Visit 0B Have reported chronic sputum
             production of â‰¥1 tablespoon (15mL) per day on the majority of days in the 3 months
             prior to Visit 0A

          8. Be able to perform all the techniques necessary to measure lung function

          9. Have FEV1 â‰¥40% predicted* and â‰¥1.0L (*according to NHANES III 1999 predicted tables)
             measured at V0B (Baseline result prior to MTT (Mannitol Tolerance Test)
             administration)

        Exclusion Criteria

          1. Be investigators, site personnel directly affiliated with this study, or their
             immediate families. Immediate family is defined as a spouse, parent, child or sibling,
             whether biologically or legally adopted.

          2. Have bronchiectasis as a consequence of cystic fibrosis or focal endobronchial lesion
             or otherwise curable causes (e.g. foreign body aspiration)

          3. Be considered &quot;terminally ill&quot; or listed for transplantation

          4. Be using hypertonic saline in the 14 days prior to commencing Visit 0B or thereafter
             at any time during the study

          5. Have previously used inhaled mannitol (Bronchitol) for more than a day

          6. Have had a significant episode of hemoptysis (&gt;60 mL) in the previous 6 months

          7. Have had rescue antibiotics in the 4 weeks prior to V0B (chronic background antibiotic
             therapy accepted)

          8. Have smoked within the last 3 months and must not smoke during their participation in
             the study

          9. Have had a myocardial infarction in the three months prior to Visit 0A

         10. Have had a cerebral vascular accident in the three months prior to Visit 0A

         11. Have had major ocular surgery in the three months prior to Visit 0A

         12. Have had major abdominal, chest or brain surgery in the three months prior to Visit 0A

         13. Have a known cerebral, aortic or abdominal aneurysm

         14. Have actively treated Mycobacterium tuberculosis

         15. Have actively treated or unstable nontuberculous mycobacterial (NTM)infection or be
             under consideration for NTM treatment in the next 12 months

         16. Have unstable Allergic bronchopulmonary aspergillosis (ABPA) requiring steroid therapy
             (â‰¤5mg dose oral steroids in stable ABPA accepted)

         17. Have end stage interstitial lung disease

         18. Have active malignancy including melanoma (other skin carcinomas exempted). Remissions
             from any malignancy â‰¥2 years also exempted

         19. Be breast feeding or pregnant, or plan to become pregnant while in the study

         20. Be using an unreliable form of contraception (female subjects at risk of pregnancy
             only)

         21. Be participating in another investigational drug study, parallel to, or within 4 weeks
             of Visit 0A

         22. Have a known intolerance to mannitol or Î²2-agonists

         23. Have uncontrolled hypertension - e.g. for adults: systolic blood pressure (BP) &gt; 190
             and or diastolic BP &gt; 100

         24. Subject has a condition or is in a situation which in the Investigator's opinion may
             put the subject at significant risk, may confound results or may interfere
             significantly with the patient's participation in the study

         25. Have previously been screen failed for the study (exceptions - see section 3.3.2
             Eligibility Criteria - Rescreening)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Bilton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brompton Hospital London UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Greg Tino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania Medical Centre, Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Barker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health Sciences University, Portland Oregon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Health Center, Pulmonary Division</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-1321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Pulmonary Research</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Hospitals</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chest Medicine Clinical Services, LLC</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Critical Care Medicine Pulmonary Clinical Research Unit</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary and Allergy Associates</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Associates of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Oregon Clinic, PC/Pulmonary Division</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Pharmaceutical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Clinical Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Richmond, Inc</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Argentino de InvestigaciÃ³n NeurolÃ³gica</name>
      <address>
        <city>Ciudad AutÃ³noma de Buenos Aires</city>
        <state>Ciudad AutÃ³noma de Buenos Aires,</state>
        <zip>C1015ABR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Privado de Medicina Respiratoria</name>
      <address>
        <city>Entre Rios</city>
        <state>ParanÃ¡ Entre RÃ­os</state>
        <zip>E3100BHK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Zonal Especializado en Agudos y Cronicos &quot;Dr Antonio A. Cetrangolo</name>
      <address>
        <city>Florida Partido de Vicente LÃ³pez</city>
        <state>Provincia de Buenos Aires</state>
        <zip>B1602DOH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Respiratorio Quilmes</name>
      <address>
        <city>Quilmes</city>
        <state>Provincia de Buenos Aires</state>
        <zip>B1878FNR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Privado - Centro Medico de Cordoba</name>
      <address>
        <city>Cordoba</city>
        <state>Provincia de Cordoba</state>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insares</name>
      <address>
        <city>Mendoza</city>
        <state>Provincia de Mendoza</state>
        <zip>M5500CCG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica del Torax</name>
      <address>
        <city>Rosario</city>
        <state>Provincia de Santa Fe</state>
        <zip>S2000DBS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Cardiovascular de Rosario</name>
      <address>
        <city>Rosario</city>
        <state>Provincia de Santa Fe</state>
        <zip>S2000DSR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque</name>
      <address>
        <city>Rosario</city>
        <state>Provincia de Santa Fe</state>
        <zip>S2000KZD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigaciones en Patologias Respiratorias</name>
      <address>
        <city>San Miguel de TucumÃ¡n</city>
        <state>Provincia de TucumÃ¡n</state>
        <zip>T4000IAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Interzonal General de Agudos &quot;Dr Jose Penna&quot;</name>
      <address>
        <city>Bahia Bianca</city>
        <state>Provinica de Buenos Aires</state>
        <zip>B8001DDU</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacion medica de General San Martin</name>
      <address>
        <city>Mathew 4071</city>
        <state>San Martin Provincia de Buenos Aires</state>
        <zip>B1650CSQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AtenciÃ³n Integral en ReumatologÃ­a (AIR)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>CP1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro MÃ©dico Dra. De Salvo</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>CP1426ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woolcock Institute of Medical Research</name>
      <address>
        <city>Glebe</city>
        <state>New South Wales</state>
        <zip>2037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Repatriation General Hospital</name>
      <address>
        <city>Daws Park</city>
        <state>South Australia</state>
        <zip>5041</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Rooms of Dr C Steinfort</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB Hopital Erasme - Department of Pneumology</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St. Luc (UCL) - Department of Pulmonology</name>
      <address>
        <city>Brussels</city>
        <zip>B-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven (University Hospital Leuven) - Depatment of Pulmonary Medicine</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago de Chile</city>
        <state>Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad de Chile</name>
      <address>
        <city>Santiago de Chile</city>
        <state>Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Talca</name>
      <address>
        <city>Talca</city>
        <zip>1990</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKF Pneumologie GmbH and Co KG</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover Klinik fÃ¼r Pneumologie</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungen und Bronchialheikunde</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologisch Studienzentrum</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>4357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar - Department of Pulmonary Medicine</name>
      <address>
        <city>Alkmaar</city>
        <state>Alkmaar AM</state>
        <zip>1800</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden (MCL) - Department of Pulmonology</name>
      <address>
        <city>Leeuwarden</city>
        <state>Leeuwarden AD</state>
        <zip>8934</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium MC -Department of Pulmonary Diseases</name>
      <address>
        <city>Heerlen</city>
        <zip>6419</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Green Lane Clinical Centre</name>
      <address>
        <city>Greenlane</city>
        <state>Auckland</state>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1640</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Wales General Hospital</name>
      <address>
        <city>Carmarthen</city>
        <state>Carmarthenshire</state>
        <zip>SA31 2AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <state>Derbyshire</state>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital</name>
      <address>
        <city>Torquay</city>
        <state>Devon</state>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <state>East Yorkshire</state>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Headington</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Shrewsbury Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <state>Shropshire</state>
        <zip>SY3 8XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Northern General Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stafford Hospital</name>
      <address>
        <city>Stafford</city>
        <state>Staffordshire</state>
        <zip>ST16 3SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashford &amp; St Peters Hospital</name>
      <address>
        <city>Chertsey</city>
        <state>Surrey</state>
        <zip>KT16 0PZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Tees</name>
      <address>
        <city>Stockton</city>
        <state>Teeside</state>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Llandough Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Vale of Glamorgan</state>
        <zip>CF64 2XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingam Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolverhampton New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <state>West Midlands</state>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 22N</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Aintree</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle-upon-Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Tyneside General Hospital</name>
      <address>
        <city>North Shields</city>
        <zip>NE29 8NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wrexham Maelor Hospital</name>
      <address>
        <city>Wrexham</city>
        <zip>LL13 7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Chile</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med. 1999 Jun;159(6):1843-8.</citation>
    <PMID>10351929</PMID>
  </reference>
  <reference>
    <citation>Daviskas E, Anderson SD, Eberl S, Young IH. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J. 2008 Apr;31(4):765-72. Epub 2007 Dec 5.</citation>
    <PMID>18057051</PMID>
  </reference>
  <reference>
    <citation>Daviskas E, Anderson SD, Young IH. Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. Respirology. 2007 Sep;12(5):683-91.</citation>
    <PMID>17875056</PMID>
  </reference>
  <reference>
    <citation>Daviskas E, Anderson SD. Hyperosmolar agents and clearance of mucus in the diseased airway. J Aerosol Med. 2006 Spring;19(1):100-9. Review.</citation>
    <PMID>16551221</PMID>
  </reference>
  <reference>
    <citation>Daviskas E, Anderson SD, Gomes K, Briffa P, Cochrane B, Chan HK, Young IH, Rubin BK. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology. 2005 Jan;10(1):46-56.</citation>
    <PMID>15691238</PMID>
  </reference>
  <reference>
    <citation>Daviskas E, Robinson M, Anderson SD, Bye PT. Osmotic stimuli increase clearance of mucus in patients with mucociliary dysfunction. J Aerosol Med. 2002 Fall;15(3):331-41. Review.</citation>
    <PMID>12396422</PMID>
  </reference>
  <reference>
    <citation>Daviskas E, Anderson SD, Eberl S, Chan HK, Young IH. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest. 2001 Feb;119(2):414-21.</citation>
    <PMID>11171717</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2008</study_first_submitted>
  <study_first_submitted_qc>April 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2008</study_first_posted>
  <results_first_submitted>November 22, 2015</results_first_submitted>
  <results_first_submitted_qc>March 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2016</results_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>randomized clinical trial</keyword>
  <keyword>mannitol</keyword>
  <keyword>mucoactive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Prior to randomisation, subjects underwent a Mannitol Tolerance Test (MTT) - only those who passed the MTT were eligible to be randomised. 581 patients in total underwent the MTT</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mannitol</title>
          <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomisation to First Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="241"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="233"/>
                <participants group_id="P2" count="228"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomised in error</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Blinded Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="233"/>
                <participants group_id="P2" count="228"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable/unwilling to comply w trial reqs</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients randomised and treated with at least one dose of study medication</population>
      <group_list>
        <group group_id="B1">
          <title>Mannitol</title>
          <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="233"/>
            <count group_id="B2" value="228"/>
            <count group_id="B3" value="461"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.30" spread="14.06"/>
                    <measurement group_id="B2" value="60.26" spread="13.02"/>
                    <measurement group_id="B3" value="59.77" spread="13.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Pulmonary Exacerbation rate</title>
          <units>events/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.20" spread="1.38"/>
                    <measurement group_id="B2" value="3.25" spread="1.40"/>
                    <measurement group_id="B3" value="3.22" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline % of Predicted FEV1</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;60%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=60%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extent of Bronchiectasis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diffuse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Focal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both (Diffuse and Focal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Graded Pulmonary Exacerbations</title>
        <description>A graded pulmonary exacerbation was defined as a worsening in signs and symptoms requiring a change in treatment (Center for Drug Evaluation and Research (CDER), 2007). Grade I was required 3 main signs and symptoms, Grade II 2 main signs and symptoms and Grade III 1 main and one or more minor signs and symptoms. Main signs and symptoms were increased cough, sputum volume or sputum purulence. Minor were upper respiratory tract infection, fever, increased wheezing, increased dyspnea, increase in respiratory rate, increase in cardiac frequency of &gt;20%, and increased malaise, fatigue or lethargy. Rate is defined as the number of all GPE events observed in one treatment year</description>
        <time_frame>52 weeks</time_frame>
        <population>Randomised and Treated (referred to as the ITT population in this trial)</population>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Graded Pulmonary Exacerbations</title>
          <description>A graded pulmonary exacerbation was defined as a worsening in signs and symptoms requiring a change in treatment (Center for Drug Evaluation and Research (CDER), 2007). Grade I was required 3 main signs and symptoms, Grade II 2 main signs and symptoms and Grade III 1 main and one or more minor signs and symptoms. Main signs and symptoms were increased cough, sputum volume or sputum purulence. Minor were upper respiratory tract infection, fever, increased wheezing, increased dyspnea, increase in respiratory rate, increase in cardiac frequency of &gt;20%, and increased malaise, fatigue or lethargy. Rate is defined as the number of all GPE events observed in one treatment year</description>
          <population>Randomised and Treated (referred to as the ITT population in this trial)</population>
          <units>GPE events per year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Raw rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95"/>
                    <measurement group_id="O2" value="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rate from negative binomial model</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69"/>
                    <measurement group_id="O2" value="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3115</p_value>
            <method>Negative binomial regression model</method>
            <method_desc>Negative binomial regression model with treatment, region and baseline PE rate as predictors and log of follow-up time as an offset variable</method_desc>
            <param_type>Rate Ratio Mannitol:Control</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>For rate ratio, Mannitol rate is the numerator, Control rate is the denominator</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the St. Georges Respiratory Questionnaire (SGRQ) Total Score</title>
        <description>The SGRQ was collected at baseline, week 6, week 16, week 28, week 40 and week 52. Change in total score was calculated from baseline. Total scores are a weighted sum across all questions. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. Higher scores indicate lower quality of life. Outcome data table gives the raw mean total score at each visit.</description>
        <time_frame>52 weeks</time_frame>
        <population>Randomised and treated with one or more post-baseline SGRQ data available</population>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the St. Georges Respiratory Questionnaire (SGRQ) Total Score</title>
          <description>The SGRQ was collected at baseline, week 6, week 16, week 28, week 40 and week 52. Change in total score was calculated from baseline. Total scores are a weighted sum across all questions. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. Higher scores indicate lower quality of life. Outcome data table gives the raw mean total score at each visit.</description>
          <population>Randomised and treated with one or more post-baseline SGRQ data available</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.98" spread="14.64"/>
                    <measurement group_id="O2" value="52.22" spread="14.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.09" spread="17.49"/>
                    <measurement group_id="O2" value="44.55" spread="18.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.67" spread="19.07"/>
                    <measurement group_id="O2" value="44.23" spread="19.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.45" spread="18.58"/>
                    <measurement group_id="O2" value="43.46" spread="19.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.39" spread="18.86"/>
                    <measurement group_id="O2" value="43.51" spread="19.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.43" spread="19.60"/>
                    <measurement group_id="O2" value="42.25" spread="19.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0457</p_value>
            <method>Mixed model repeated measures analysis</method>
            <method_desc>Model included treatment, visit, treatment*visit, region and baseline SGRQ Total score.</method_desc>
            <param_type>LS mean difference across the 52 weeks</param_type>
            <param_value>-2.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.76</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
            <estimate_desc>difference calculated Mannitol-control. Negative difference is in favour of mannitol since lower scores indicate improved quality of life.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibiotic Use Prescribed for Treated Pulmonary Exacerbations</title>
        <description>Rate of antibiotic treated graded pulmonary exacerbations, using the same definition of a graded pulmonary exacerbation as the primary endpoint. A graded pulmonary exacerbation was considered to be anti-biotic treated if use of oral, IV or inhaled antibiotic use was recorded related to the GPE event.</description>
        <time_frame>52 weeks</time_frame>
        <population>Randomised and treated (referred to as ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Antibiotic Use Prescribed for Treated Pulmonary Exacerbations</title>
          <description>Rate of antibiotic treated graded pulmonary exacerbations, using the same definition of a graded pulmonary exacerbation as the primary endpoint. A graded pulmonary exacerbation was considered to be anti-biotic treated if use of oral, IV or inhaled antibiotic use was recorded related to the GPE event.</description>
          <population>Randomised and treated (referred to as ITT)</population>
          <units>events/year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2754</p_value>
            <method>Negative binomial regression model</method>
            <method_desc>Negative binomial regression model with treatment, region and baseline pulmonary exacerbation rate as predictors, log follow-up as offset</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Rate ratio is for mannitol vs control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Graded Exacerbation</title>
        <description>Time to first graded exacerbation is defined as the duration (in months) from the randomisation date to the start of the first reported graded PE during the on-treatment period. Patients without reported graded PE event will be censored at the last participation.</description>
        <time_frame>52 weeks</time_frame>
        <population>Randomised and treated</population>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Graded Exacerbation</title>
          <description>Time to first graded exacerbation is defined as the duration (in months) from the randomisation date to the start of the first reported graded PE during the on-treatment period. Patients without reported graded PE event will be censored at the last participation.</description>
          <population>Randomised and treated</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="4.1" upper_limit="6.7"/>
                    <measurement group_id="O2" value="4.1" lower_limit="3.5" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0218</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model was stratified by region and baseline PE rate</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Graded Exacerbations</title>
        <description>Duration of graded exacerbations is defined as the number of days with graded PE within one treatment year. Mean days estimated via negative binomial model with treatment, region and baseline pulmonary exacerbation rate as predictors, with log of follow-up time as the offset variable</description>
        <time_frame>52 weeks</time_frame>
        <population>Randomised and treated</population>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Graded Exacerbations</title>
          <description>Duration of graded exacerbations is defined as the number of days with graded PE within one treatment year. Mean days estimated via negative binomial model with treatment, region and baseline pulmonary exacerbation rate as predictors, with log of follow-up time as the offset variable</description>
          <population>Randomised and treated</population>
          <units>Days with GPE</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.49" lower_limit="25.54" upper_limit="38.82"/>
                    <measurement group_id="O2" value="35.74" lower_limit="28.90" upper_limit="44.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysed using a negative binomial model with treatment, region and baseline pulmonary exacerbation rate as predictors, and with log of follow-up time as the offset variable</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3602</p_value>
            <method>Negative binomial model</method>
            <method_desc>treatment, region and baseline pulmonary exacerbation rate as predictors, and with log of follow-up time as the offset variable</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Volume</title>
        <description>24 hour sputum weight, measured at baseline, week 6, week 16, week 28, week 40, week 52</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Volume</title>
          <description>24 hour sputum weight, measured at baseline, week 6, week 16, week 28, week 40, week 52</description>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.88" spread="18.71"/>
                    <measurement group_id="O2" value="28.96" spread="19.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.97" spread="23.17"/>
                    <measurement group_id="O2" value="22.82" spread="20.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.69" spread="22.09"/>
                    <measurement group_id="O2" value="20.25" spread="16.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.92" spread="25.66"/>
                    <measurement group_id="O2" value="18.88" spread="17.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.56" spread="21.58"/>
                    <measurement group_id="O2" value="18.17" spread="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.54" spread="24.07"/>
                    <measurement group_id="O2" value="18.33" spread="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0355</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, visit, treatment*visit, region and baseline sputum weight (g).</method_desc>
            <param_type>ls mean difference across 52 weeks</param_type>
            <param_value>2.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>5.33</ci_upper_limit>
            <estimate_desc>Difference mannitol-control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Sleepiness Scores</title>
        <description>Epworth Sleepiness Scale (ESS) score was calculated as the sum of scores for each of eight individual questions, such that a total score of zero represents no daytime sleepiness, and a total score of 24 represents the maximum degree of daytime sleepiness. Measured at baseline, 6 weeks, 16 weeks, 28 weeks, 40 weeks, 52 weeks</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Sleepiness Scores</title>
          <description>Epworth Sleepiness Scale (ESS) score was calculated as the sum of scores for each of eight individual questions, such that a total score of zero represents no daytime sleepiness, and a total score of 24 represents the maximum degree of daytime sleepiness. Measured at baseline, 6 weeks, 16 weeks, 28 weeks, 40 weeks, 52 weeks</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="4.85"/>
                    <measurement group_id="O2" value="6.89" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.07" spread="4.78"/>
                    <measurement group_id="O2" value="6.87" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.21" spread="5.10"/>
                    <measurement group_id="O2" value="6.50" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" spread="4.73"/>
                    <measurement group_id="O2" value="6.57" spread="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.32" spread="5.10"/>
                    <measurement group_id="O2" value="6.33" spread="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" spread="4.98"/>
                    <measurement group_id="O2" value="6.34" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1159</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model includes treatment, visit, treatment*visit, region and baseline ESS score</method_desc>
            <param_type>LS mean diff across post-baseline visits</param_type>
            <param_value>-0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
            <estimate_desc>Negative change indicates an improvement in ESS score. Difference calculated Mannitol - Control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Change in FEV1 (Forced Expiratory Volume in One Second)</title>
        <time_frame>52 weeks</time_frame>
        <population>Randomised and treated with at least one post-baseline spirometry assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Change in FEV1 (Forced Expiratory Volume in One Second)</title>
          <population>Randomised and treated with at least one post-baseline spirometry assessment</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" lower_limit="-24.03" upper_limit="28.74"/>
                    <measurement group_id="O2" value="-5.20" lower_limit="-32.35" upper_limit="21.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6677</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model of absolute change from baseline in FEV1. Model includes terms for treatment, visit, trt*visit, region and baseline value</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>7.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.01</ci_lower_limit>
            <ci_upper_limit>42.13</ci_upper_limit>
            <estimate_desc>ls mean difference Mannitol-Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Change in FVC (Forced Vital Capacity)</title>
        <time_frame>52 weeks</time_frame>
        <population>Randomised and treated with at least one post-baseline spirometry assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Change in FVC (Forced Vital Capacity)</title>
          <population>Randomised and treated with at least one post-baseline spirometry assessment</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="-36.75" upper_limit="37.05"/>
                    <measurement group_id="O2" value="-15.70" lower_limit="-53.64" upper_limit="22.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Change in FEV1/FVC</title>
        <description>FEV1 expressed as a ratio of FVC. Endpoint is expressed as a percentage ie FEV1/FVC*100</description>
        <time_frame>52 weeks</time_frame>
        <population>Randomised and treated with at least one post-baseline spirometry assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Change in FEV1/FVC</title>
          <description>FEV1 expressed as a ratio of FVC. Endpoint is expressed as a percentage ie FEV1/FVC*100</description>
          <population>Randomised and treated with at least one post-baseline spirometry assessment</population>
          <units>ratio (expressed as a %)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" lower_limit="-0.68" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.09" lower_limit="-0.52" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function - Change in FEF25-75 (Forced Expiratory Flow Rate Averaged Over 25th -75th Percentile of FVC)</title>
        <time_frame>52 weeks</time_frame>
        <population>Randomised and treated with at least one post-baseline spirometry assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function - Change in FEF25-75 (Forced Expiratory Flow Rate Averaged Over 25th -75th Percentile of FVC)</title>
          <population>Randomised and treated with at least one post-baseline spirometry assessment</population>
          <units>mL/s</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.21" lower_limit="-59.09" upper_limit="22.67"/>
                    <measurement group_id="O2" value="-3.40" lower_limit="-45.28" upper_limit="38.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Profile - Sputum Microbiology</title>
        <description>sputum microbiology assessed as the presence of abnormal flora in sputum sample taken at any post baseline visit</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Profile - Sputum Microbiology</title>
          <description>sputum microbiology assessed as the presence of abnormal flora in sputum sample taken at any post baseline visit</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Profile - Clinical Chemistry</title>
        <description>Clinical chemistry was assessed as clinically significant abnormal liver function test and clinically significant abnormal urea/electrolyte test at any point post baseline.</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Profile - Clinical Chemistry</title>
          <description>Clinical chemistry was assessed as clinically significant abnormal liver function test and clinically significant abnormal urea/electrolyte test at any point post baseline.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with Clin sig liver funtion tests at wk52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with clin sig urea/electrolyte test wk52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Profile - Hematology</title>
        <description>hematology assessed as clinically significant abnormal FBC (Full Blood count) at any point post baseline.</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Profile - Hematology</title>
          <description>hematology assessed as clinically significant abnormal FBC (Full Blood count) at any point post baseline.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>â€¢ (Exploratory) Number of Hospitalizations Due to Pulmonary Exacerbations</title>
        <description>Mean rate of hospitalisations (number/year) summarised and analysed to take account of differing follow-up times.</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>â€¢ (Exploratory) Number of Hospitalizations Due to Pulmonary Exacerbations</title>
          <description>Mean rate of hospitalisations (number/year) summarised and analysed to take account of differing follow-up times.</description>
          <units>hospitalisations/year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.07" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.20" lower_limit="0.13" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0928</p_value>
            <method>Negative binomial regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Health Related Costs of Treating Patients With Bronchiectasis</title>
        <description>In the presence of a significant primary endpoint, these data were intended to be derived using the trial data together with external information (Note as the primary objective of this study did not reach statistical significance, health related costs were not assessed)</description>
        <time_frame>52 weeks</time_frame>
        <population>No data were collected. Since the primary objective was not significant in this study, further exploration of health economic endpoints was not done.</population>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol 400mg
Inhaled mannitol: 400mg dose of Mannitol BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control - inhaled mannitol 50mg
Matched control: 50mg dose of Mannitol BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Costs of Treating Patients With Bronchiectasis</title>
          <description>In the presence of a significant primary endpoint, these data were intended to be derived using the trial data together with external information (Note as the primary objective of this study did not reach statistical significance, health related costs were not assessed)</description>
          <population>No data were collected. Since the primary objective was not significant in this study, further exploration of health economic endpoints was not done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Health Status and Utility Scores</title>
        <description>In the presence of a significant primary endpoint, these data were intended to be derived from the trial data and external information (Note as the primary objective of this study did not reach statistical significance, differences in health status and utility scores were not assessed)</description>
        <time_frame>52 weeks</time_frame>
        <population>No data were collected. As the primary objective of this study did not reach statistical significance, health status and utility scores were not derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Health Status and Utility Scores</title>
          <description>In the presence of a significant primary endpoint, these data were intended to be derived from the trial data and external information (Note as the primary objective of this study did not reach statistical significance, differences in health status and utility scores were not assessed)</description>
          <population>No data were collected. As the primary objective of this study did not reach statistical significance, health status and utility scores were not derived.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Health Related Quality of Life (HRQL) and Quality Adjusted Life Years (QALYs) by Treatment Group Using Utility Scores From the Health Utilities Index Questionnaire</title>
        <description>In the presence of a significant primary endpoint, these data were intended to be derived using the trial data and external information (Note as the primary objective of this study did not reach statistical significance, HRQL and QALYs were not collected).</description>
        <time_frame>52 weeks</time_frame>
        <population>No data were collected for this assessment. As the primary objective of this study did not reach statistical significance, HRQL and QALYs were not derived.</population>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality of Life (HRQL) and Quality Adjusted Life Years (QALYs) by Treatment Group Using Utility Scores From the Health Utilities Index Questionnaire</title>
          <description>In the presence of a significant primary endpoint, these data were intended to be derived using the trial data and external information (Note as the primary objective of this study did not reach statistical significance, HRQL and QALYs were not collected).</description>
          <population>No data were collected for this assessment. As the primary objective of this study did not reach statistical significance, HRQL and QALYs were not derived.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cost Effectiveness of Treating Patients With Bronchiectasis With Inhaled Mannitol</title>
        <description>In the presence of a significant primary endpoint, these data were intended to be derived using the trial data and external information (Note as the primary objective of this study did not reach statistical significance, cost effectiveness was not collected).</description>
        <time_frame>52 weeks</time_frame>
        <population>Not collected. As the primary objective of this study did not reach statistical significance, cost effectiveness data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Mannitol</title>
            <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Cost Effectiveness of Treating Patients With Bronchiectasis With Inhaled Mannitol</title>
          <description>In the presence of a significant primary endpoint, these data were intended to be derived using the trial data and external information (Note as the primary objective of this study did not reach statistical significance, cost effectiveness was not collected).</description>
          <population>Not collected. As the primary objective of this study did not reach statistical significance, cost effectiveness data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mannitol</title>
          <description>Inhaled mannitol
Inhaled mannitol: 400mg BD for 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Matched control: Inhaled mannitol 50mg BD for 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Condition Aggravated</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Disease prodomal stage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Dacryocystisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Swine Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Skin lacreation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Pharyngeal pouch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bladder repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <description>INCLUDES SERIOUS ADVERSE EVENTS ALSO</description>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <description>INCLUDES SERIOUS ADVERSE EVENTS ALSO</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bacteia sputum identified</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Dsypnoea</sub_title>
                <description>INCLUDES SERIOUS ADVERSE EVENTS ALSO</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <description>INCLUDES SERIOUS ADVERSE EVENTS ALSO</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="228"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="233"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="228"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Relatively few studies in this area -ideal choice of endpoints not well-defined. No widely accepted exacerbation definition. Relies on patientsâ€™ accurate &amp; timely symptom reporting.Unclear event end-dates may impact on counting of subsequent events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Brett Charlton, Medical Director</name_or_title>
      <organization>Pharmaxis Ltd</organization>
      <phone>+61 2 94547210</phone>
      <email>brett.charlton@pharmaxis.com.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

